ABOS
NASDAQ:ABOS
Acumen Pharmaceuticals, Inc.
- Stock
1.07
−5.31%
−0.50
news - Jul 18, 2025 - 09:01
Weekly Rundown: Merck advances once-monthly HIV pill to Phase 3
The article covers major developments in biotech and pharmaceuticals, including Merck's advancement of its HIV prevention pill MK-8527 to Phase 3 trials, Takeda's positive results for narcolepsy drug oveporexton, the FDA's release of 200+ drug rejection letters, rejections of advanced therapies by the FDA, concerns over GSK's Blenrep drug, and a collaboration between JCR and Acumen to address Alzheimer's drug delivery challenges.
drugdiscoverynews.comnews - Jul 15, 2025 - 02:00
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
JCR Pharmaceuticals and Acumen Pharmaceuticals announced a collaboration to develop a novel Alzheimer’s therapy using JCR’s J-Brain Cargo® technology, which enables blood-brain barrier penetration. The partnership includes upfront payments, milestone payments up to $555 million, and tiered royalties. The technology has been clinically validated with IZCARGO® in Japan.
businesswire.comnews - Jun 18, 2025 - 08:16
Acumen Pharmaceuticals (NASDAQ:ABOS) Now Covered by Citigroup
Citigroup initiated coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating and $4.00 price target. UBS Group and HC Wainwright also issued buy ratings with revised price targets. The company reported Q2 earnings of ($0.48) EPS, exceeding estimates, and analysts predict -1.56 EPS for the year. Institutional investors including Susquehanna, Clune, and Jane Street adjusted their holdings in the fourth quarter.
defenseworld.netnews - Jun 17, 2025 - 02:00
Citigroup Initiates Coverage on Acumen Pharmaceuticals (ABOS) with 'Buy' Rating | ABOS Stock News
Citigroup has initiated coverage on Acumen Pharmaceuticals (ABOS) with a 'Buy' rating, assigning a price target of $4.00 USD. Analysts' average target price is $8.75, implying a 667.54% upside from the current price of $1.14. The average brokerage recommendation is 1.4, indicating 'Buy' status.
gurufocus.comnews - Jun 04, 2025 - 15:53
Alzheimers Drugs Market Is Booming So Rapidly 2025-2032
The global Alzheimer's drugs market is projected to grow from USD 5.64 billion in 2025 to USD 11.34 billion by 2032, with a compound annual growth rate (CAGR) of 10.5%. The report by Coherent Market Insights analyzes market trends, competitive landscape, and key drivers, including technological innovation, pricing trends, and investment opportunities.
openpr.comDescription
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorpora...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus